Technical analysis of Cingulate Inc. (CING): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine).
Price Performance
| 1 month | -1.15% |
| 3 months | +3.01% |
| Year-to-date | +18.43% |
| 1 year | +38.92% |
| 3 years | -96.89% |
52-Week Range
| 52-week High | $11.89 |
| 52-week Low | $3.16 |
| Avg Volume (90d) | 365K |
Technical Indicators
| SMA 50 | $5.03 |
| SMA 200 | $5.34 |
| Beta | -0.77 |
| 30-day Volatility (annualised) | 42.9% |
| Price vs SMA 50 | +2.3% |
| Price vs SMA 200 | -3.7% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $3.79 | |
| 2025-11 | $3.73 | -1.6% |
| 2025-12 | $4.34 | +16.4% |
| 2026-01 | $5.74 | +32.3% |
| 2026-02 | $6.27 | +9.2% |
| 2026-03 | $6.21 | -1.0% |
| 2026-04 | $5.15 | -17.1% |
| 2026-05 | $4.16 | -19.2% |
| 2026-06 | $5.47 | +31.5% |
| 2026-07 | $4.79 | -12.4% |
| 2026-08 | $5.17 | +7.9% |
| 2026-09 | $5.14 | -0.6% |
Price
| Price | $5.09 |
| Market Cap | $69M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.13 |
| EV / EBITDA | -1.10 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.27 |
| Current Ratio | 3.50 |